Document Type : Research Paper
Authors
1 Assistant Professor of Sport Physiology, Tarbiat Modares University
2 Assistant Professor of Immunology, Pasteur Institute of Iran
3 M.Sc. of Sport Physiology, Islamic Azad University, Taft Branch
Abstract
For vaccine efficacy always using adjuvant has been considered by immunologists. Exercise can induce immune changes, and therefore, has been identified as an adjuvant for immune responses. The purpose of this study was to assess adjuvant effects of an acute endurance exercise on interleukin-2 and interleukin-12 cytokines of spleen cells in herpes simplex virus 1 vaccine model. 24 BALB/c mice, 4 to 5 weeks old and with an average weight of 17.6 g, were divided into 3 groups: control, vaccine and vaccine plus an acute endurance exercise. Two weeks after three booster shots of vaccine, interleukin-2 and interleukin-12 levels was determined in spleen cell culture with ELISA method. One-ways ANOVA statistical test were used for data analysis. The result of this study indicated that there are significant differences between groups in interleukin-2 (P=0.008). Tukey post hoc test results showed significant differences between control and vaccine plus an acute endurance exercise groups (P=0.006). Changes in interleukin-12 cytokine production in vaccine and endurance exercise group were not significant. Result of current study showed that interleukin-2 levels from spleen cells increased following using an acute endurance exercise as an adjuvant. It seems that using an acute endurance exercise probably increased efficacy of immune system in direction to T helper 1 cells against virus infections.
Keywords
Main Subjects
2. Frauwirth K A, Thompson C B. Regulation of T lymphocyte metabolism. J Immunol. 2004; 172(8): 4661-5.
3. Miyazaki T, Liu Z J, Kawahara A, Minami Y, Yamada K, Tsujimoto Y, et al. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell. 1995; 81(2): 223-31.
4. Koshland M E. The coming of age of the immunoglobulin J chain. Annu Rev Immunol. 1985; 3: 425-53.
5. Giri J G, Kumaki S, Ahdieh M, Friend D J, Loomis A, Shanebeck K, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 1995; 14(15): 3654-63.
6. Gaffen S L, Liu K D. Overview of interleukin-2 function, production and clinical applications. Cytokine. 2004; 28(3): 109-23.
7. Marshall J D, Secrist H, DeKruyff R H, Wolf S F, Umetsu D T. IL-12 inhibits the production of IL-4 and IL-10 in allergen-specific human CD4+T lymphocytes. J Immunol. 1995; 155(1): 111-7.
8. Chehimi J, Trinchieri G. Interleukin-12: A bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol. 1994; 14(3): 149-61.
9. Khatri V P, Fehniger T A, Baiocchi R A, Yu F, Shah M H, Schiller D S, et al. Ultra-low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J Clin Invest. 1998; 101(6): 1373-8.
10. Koelle D M. Vaccines for herpes simplex virus infections. Curr Opin Investig Drugs. 2006; 7(2): 136-41.
11. Whitley R J, Roizman B. Herpes simplex viruses: Is a vaccine tenable? Journal of Clinical Investigation. 2002; 110(2): 145-51.
12. Liu T, Khanna K M, Chen X, Fink D J, Hendricks R L. CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med. 2000; 191(9): 1459-66.
13. Halford W P, Maender J L, Gebhardt B M. Re-evaluating the role of natural killer cells in innate resistance to herpes simplex virus type 1. Virol J. 2005; 2: 56.
14. Gallichan W S, Woolstencroft R N, Guarasci T, McCluskie M J, Davis H L, Rosenthal K L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. The Journal of Immunology. 2001; 166(5): 3451-7.
15. Janeway Ca Jr, Travers P, Walport M. Immunobiology: The immune system in health and disease. 5th ed. New York: Garland Science; 2001.
16. Edwards K M, Burns V E, Carroll D, Drayson M, Ring C. The acute stress-induced immunoenhancement hypothesis. Exerc Sport Sci Rev. 2007; 35(3): 150-5.
17. Rock K L, Hearn A, Chen C J, Shi Y. Natural endogenous adjuvants. Springer Semin Immunopathol. 2005; 26(3): 231-46.
18. Pascoe A R, Fiatarone Singh M A, Edwards K M. The effects of exercise on vaccination responses: A review of chronic and acute exercise interventions in humans. Brain Behav Immun. 2014; 39: 33-41.
19. Rogers C J, Zaharoff D A, Hance K W, Perkins S N, Hursting S D, Schlom J, et al. Exercise enhances vaccine-induced antigen-specific T cell responses. Vaccine. 2008; 26(42): 5407-15.
20. Molanouri Shamsi M, Hassan Z M, Quinn L S, Gharakhanlou R, Baghersad L, Mahdavi M. Time course of IL-15 expression after acute resistance exercise in trained rats: Effect of diabetes and skeletal muscle phenotype. Endocrine. 2015; 49(2): 396-403. (In Persian).
21. Azimian E, Ranjbar R, Shakerian S, Habibi A, Ghafourian M. Comparison of an acute bout of combined exercise training in different intensities on tumor necrosis factor- α (TNFα) and interlokin-6 (IL-6) in active men. Sport Physiology Journal. 2016; 28: 87-102. (In Persian).
22. Nieman D C. Exercise effects on systemic immunity. Immunology and Cell Biology. 2000; 78: 496–501.
23. Magalhães J, Fraga M, Lumini-Oliveira J, Gonçalves I, Costa M, Ferreira R, et al. Eccentric exercise transiently affects mice skeletal muscle mitochondrial function. Appl Physiol Nutr Metab. 2013; 38(4): 401-9.
24. Lowder T, Padgett D A, Woods J A. Moderate exercise protects mice from death due to influenza virus. Brain Behav Immun. 2005; 19(5): 377-80.
25. Davis J M, Kohut M L, Colbert L H, Jackson D A, Ghaffar A, Mayer E P. Exercise, alveolar macrophage function, and susceptibility to respiratory infection. J Appl Physiol. 1997; 83(5): 1461-6.
26. Edwards K M, Burns V E, Adkins A E, Carroll D, Drayson M, Ring C. Meningococcal a vaccination response is enhanced by acute stress in men. Psychosomatic Medicine. 2008; 70(2): 147-51.
27. Edwards K M, Burns V E, Allen L M, McPhee J S, Bosch J A, Carroll D, et al. Eccentric exercise as an adjuvant to influenza vaccination in humans. Brain Behav Immun. 2007; 21(2): 209-17.
28. Bruunsgaard H, Hartkopp A, Mohr T, Konradsen H, Heron I, Mordhorst Ch, et al. In vivo cell-mediated immunity and vaccination response following prolonged, intense exercise. Med Sci Sports Exerc. 1997; 29(9): 1176-81.
29. Kakanis M W, Peake J, Brenu E W, Simmonds M, Gray B, Hooper S L, et al. The open window of susceptibility to infection after acute exercise in healthy young male elite athletes. Exerc Immunol Rev. 2010; 16: 119-37.
30. Long J E, Ring C, Drayson M, Bosch J, Campbell J P, Bhabra J, et al. Vaccination response following aerobic exercise: Can a brisk walk enhance antibody response to pneumococcal and influenza vaccinations? Brain Behav Immun. 2012; 26(4): 680-7.
31. Pedersen B K, Steensberg A, Schjerling P. Muscle-derived interleukin-6: Possible biological effects. J Physiol. 2001; 536(Pt 2): 329-37.
32. Black S, De Gregorio E, Rappuoli R. Developing vaccines for an aging population. Sci Transl Med. 2015, 7(281): 281-8.
33. Boraschi D, Italiani P. Immunosenescence and vaccine failure in the elderly: Strategies for improving response. Immunol Lett. 2014; 162(1 Pt B): 346-53.
34. Kuo T, Wang C, Badakhshan T, Chilukuri S, Ben Mohamed L. The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine. Vaccine. 2014; 32(50): 6733-45.
35. St Leger A J, Hendricks R L. CD8+ T cells patrol HSV-1-infected trigeminal ganglia and prevent viral reactivation. J Neurovirol. 2011; 17(6): 528-34.
36. Rabinowich H, Herberman R B, Whiteside T L. Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells. Cell Immunol. 1993; 152(2): 481-98.
37. Kaufman H L, Flanagan K, Lee C S, Perretta D J, Horig H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine. 2002; 20(13-14): 1862-9.
38. Spruance S L, Evans T G, McKeough M B, Thai L, Araneo B A, Daynes R A, et al. Th1/ Th2-like immunity and resistance to herpes simplex labialis. Antiviral Res. 1995; 28(1): 39-55.
39. Xu M, Lepisto A J, Hendricks R L. CD154 signaling regulates the Th1 response to herpes simplex virus-1 and inflammation in infected corneas. J Immunol. 2004; 173(2): 1232-9.
40. Tomljenovic L, Shaw C A. Aluminum vaccine adjuvants: Are they safe? Curr Med Chem. 2011; 18(17): 2630-7.
41. Gupta R K, Siber G R. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine. 1995; 13(14): 1263-76.
)